GEOVAX Explosiver IMPFSTOFF-Kandidat!! - 500 Beiträge pro Seite
eröffnet am 04.05.20 21:48:03 von
neuester Beitrag 11.06.20 09:06:38 von
neuester Beitrag 11.06.20 09:06:38 von
Beiträge: 4
ID: 1.324.353
ID: 1.324.353
Aufrufe heute: 0
Gesamt: 520
Gesamt: 520
Aktive User: 0
ISIN: US3736784089
0,2678
USD
-7,67 %
-0,0223 USD
Letzter Kurs 25.09.20 Nasdaq OTC
Feedback
GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development -
20.04.2020,
GeoVax’s current development programs are focused on preventive vaccines against COVID-19, HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against chronic Hepatitis B infections and multiple cancers. The Company has developed preventive HIV vaccine candidate (GOVX-B11) for the clade B subtype of HIV prevalent in the Americas, Western Europe, Japan, and Australia and the clade C subtype prevalent in Africa and India. GOVX-B11 is scheduled for inclusion in an upcoming human clinical trial managed by the HVTN with the support of the National Institutes of Health (NIH). GeoVax’s clade B HIV vaccine is also part of collaborative efforts to develop an immunotherapy as a functional cure for HIV.
GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development | wallstreet-online.de - :
20.04.2020,
GeoVax’s current development programs are focused on preventive vaccines against COVID-19, HIV, Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against chronic Hepatitis B infections and multiple cancers. The Company has developed preventive HIV vaccine candidate (GOVX-B11) for the clade B subtype of HIV prevalent in the Americas, Western Europe, Japan, and Australia and the clade C subtype prevalent in Africa and India. GOVX-B11 is scheduled for inclusion in an upcoming human clinical trial managed by the HVTN with the support of the National Institutes of Health (NIH). GeoVax’s clade B HIV vaccine is also part of collaborative efforts to develop an immunotherapy as a functional cure for HIV.
GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development | wallstreet-online.de - :
Antwort auf Beitrag Nr.: 63.560.823 von kgunther am 04.05.20 21:48:03Geovax is hopeless POS
Pardon, was ist "POS" ?
Antwort auf Beitrag Nr.: 63.665.476 von kgunther am 13.05.20 17:22:52Piece of shit
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,24 | |
| +1,81 | |
| -1,69 | |
| -2,76 | |
| -3,69 | |
| -0,50 | |
| +2,26 | |
| +2,30 | |
| -0,22 | |
| -0,07 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 239 | ||
| 102 | ||
| 81 | ||
| 78 | ||
| 77 | ||
| 53 | ||
| 40 | ||
| 38 | ||
| 36 | ||
| 34 |
